CENTRAL MACULAR THICKNESS IN FINGOLIMOD TREATED MULTIPLE SCLEROSIS PATIENTS, A LOCAL EXPERIENCE
Professor Alya Abood Kareem Al Ajeeli* and Nawfal Raoof Hamzah
ABSTRACT
Background: Multiple sclerosis is a demyelinating disease of the central nervous system and is one of the commonest causes of optic neuritis. Fingolimod is the first United States Food and Drug Administration-approved orally-given agent for the treatment and modification of relapsing-remitting forms of multiple sclerosis. Fingolimod-associated macular edema is a well-recognized risk for its use in a renal indication. Aim of the Study: To evaluate the effect of fingolimod on central macular thickness in patients with multiple sclerosis. Patients & Methods: a prospective observational cross sectional study was conducted on a sample of Iraqi patients with multiple sclerosis treated with fingolimod during the period from June 2019 to October 2020, in which 156 eyes of 78 patients were assessed and followed up for one year to evaluate the development of macular edema by measuring central macular thickness, using optical coherence tomography. Results: 78 patients participated in the study, their mean age was 39 ± 10.6 years, the most frequent age group was 30-
[Full Text Article] [Download Certificate]